Despite the increasing sophistication of methods for detecting and diagnosing cancer, these methods fail to reveal a primary site of origin for a subset of patients with metastatic disease. Histopathology, the traditional cornerstone of cancer diagnosis, relies on cell morphology and tissue architecture, but can be subjective. Immunohistochemical analysis of specific tumor markers, in addition to histology and clinical findings, also aids in a differential cancer diagnosis, but can be subjective or misinterpreted as well, since many metastatic tumors do not retain the morphologic or phenotypic characteristics of their organ of origin. 
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Case Report
A 63-year-old woman with a history of breast cancer presented during a routine visit with severe epigastric pain radiating to her back, anorexia, and weight loss (15lb over two months). A positron emission tomographycomputed tomography scan showed a large pancreatic mass and diffuse retroperitoneal and pelvic lymphadenopathy (see Figure 1A) . A definitive diagnosis was needed because therapy and prognosis would be significantly affected depending on whether it was metastatic pancreatic carcinoma or breast carcinoma, so we ordered the 92-gene assay for molecular cancer classification (Cancer TYPE ID). The 92-gene assay predicted a strong likelihood for breast carcinoma as the patient's biopsy sample demonstrated significant similarity to breast cancer (P = 2.4 x 10-7).
The patient was started on chemotherapy with paclitaxel and carboplatin plus trastuzumab, and achieved complete remission after only about three months of chemotherapy (see Figure 1B ). This is a regimen known to be active in breast carcinoma but not in pancreatic carcinoma.
Discussion
Metastasis to the pancreas is much less common than primary pancreatic carcinoma. Breast carcinoma commonly metastasizes to distant organs such as the lung, bones, liver, or brain, but metastases from breast carcinoma to the pancreas are relatively less common. The patient's presentation of abdominal pain is one of the most common presenting symptoms for primary pancreatic carcinoma.
More than 43,000 people develop exocrine pancreatic cancer each year in the US and, because of its aggressive character and the fact that most patients present with relatively advanced disease, most die from the disease. Median survival is eight to 12 months for patients with locally advanced unresectable disease and only three to six months for those who present with metastases.
Although metastatic breast cancer is unlikely to be cured, meaningful improvements in survival have been seen with the introduction of newer systemic therapies. Median overall survival approaches two years, with a range from a few months to many years. 36 The patient discussed above was treated with combination therapy specific for metastatic breast carcinoma and not pancreatic carcinoma and still we achieved complete remission. This also confirms that her diagnosis by genetic assay was accurate. These results highlight the premise that accurate diagnosis of the primary site is critical for effective, site-specific cancer therapy. n 
